The Phase III MITIGATE trial demonstrated that Uplizna (inebilizumab) significantly reduces the risk of flares, lowers ...
In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.
These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...
As Amgen waits for an FDA decision on a second indication for its B cell-depleting therapy Uplizna, it has new data suggesting a third may be coming down the pipe. New data from the phase 3 MINT ...
It has some rivals in its push to the IgG4-RD market, notably Amgen which reported positive topline results from a phase 3 trial of its CD19-directed antibody Uplizna (inebilizumab), acquired as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results